ABT-143

DRUG5 trials

Sponsors

AstraZeneca

Conditions

Adverse EventsDyslipidemia, Hypercholesterolemia, HypertriglyceridemiaHealthyPharmacokineticPharmacokinetic Variables

Phase 1

Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Relative to That From the Co-administration of ABT-335 and Rosuvastatin Calcium

CompletedNCT00681395

AstraZenecaAdverse Events, Pharmacokinetic

Start: 2008-05-31Updated: 2012-09-28

Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Capsules Relative to That From Co-administration of ABT-335 and Rosuvastatin for the 5/45mg Dosage Form.

CompletedNCT00728780

AstraZenecaAdverse Events, Pharmacokinetic Variables

Start: 2008-08-31Updated: 2012-09-28

Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) and Rosuvastatin Calcium

CompletedNCT00808678

AstraZenecaHealthy

Start: 2008-12-31Updated: 2012-09-28

Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From 5/45 mg Strength of ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) 45 mg and Rosuvastatin Calcium 5 mg

CompletedNCT00826358

AstraZenecaHealthy

Start: 2008-11-30Updated: 2012-09-28

Phase 3

Safety and Efficacy Study Comparing ABT-143 to Simvastatin in Subjects With Elevated Levels of Low Density Lipoprotein Cholesterol (Bad Cholesterol) and Triglycerides

CompletedNCT00812955

AstraZenecaDyslipidemia, Hypercholesterolemia, Hypertriglyceridemia

Start: 2008-11-30End: 2009-06-30Updated: 2012-10-03

Related Papers

Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study.

2010-01-0125 citations